Treatment with Vitamin C (Ascorbic acid tablets). Ineffective and does not relief symptoms, according to a 5 high quality studies with 622 adults. Seems safe.
Avoid this treatment:
It is ineffective and does not relief the symptoms of CMT. Side effects seem minor.
Any excess of Vitamin C (Ascorbic acid) is evacuated from our body through the urine. This makes vitamin C pretty safe even in high dosages.
Ascorbic Acid tablets
Adults with Charcot Marie Tooth disease, 16 to 65 years old
Daily dosage of 1-2 grams in most cases
Treatments of Charcot Marie Tooth disease symptoms (hereditary motor and sensory neuropathy)
Ineffective, does not ease symptoms, according to 5 high quality studies.
Up to 2 grams of Vitamin C per day seems safe for adults and has no side effects. Doctor consultation is needed for diabetic adults or when in taking iron.
Charcot Marie Tooth disease (hereditary motor and sensory neuropathy)
Symptoms and signs:
Decreased ability to run, decreased sensation in legs, foot drop, frequent tripping, hammer toe, high foot arches, higher than normal steps, loss of feeling in legs, muscle pain, stork leg, weakness in the forearms, weakness in the hands and weakness in the legs.
Difficulties to walk, injuries, difficulties to breath, swallow or speak
Vitamin C (supplement)
Visitors at this page also visited
Vitamin C, also known as ascorbic acid and L-ascorbic acid, is a vitamin found in food and used as a dietary supplement. As a supplement it is used to treat and prevent scurvy. Evidence does not support use in the general population for the prevention of the common cold. It may be taken by mouth or by injection. It is generally well tolerated. Vitamin C was discovered in 1912, isolated in 1928, and first made in 1933. (source)
Similar pages on this site
Good to know
Astroturf - manipulation of media messages
Sharyl Attkisson at TEDx, University of Nevada
Sharing as the future of Medicine
Dear Doctors, here is an article about practice challenges you should seriously consider.
Personal Genetic Testing Is Here. Do We Need It?
Anahad O'Connor, The New York Times